Antibody-Drug Conjugates (ADC) molecules utilize specific antibodies to deliver therapeutic small molecules specifically to cancer cells. ADC are created in cooperation with Bai-Li Pharmaceutical's R&D Center of Excellence and enable the development of sophisticated chemistries that give this class of drugs their therapeutic payload. This advanced functional class is referred to as Heterogeneity overcoming - Immunogenic death inducing - Resistance antagonizing - Enhanced Specificity (HIRE) molecules that target cancer cells.

The ADC BL-M02D1 is a TROP2 specific antibody-drug conjugate. Due to its TROP2 binding, BL-M02D1 has rapid internalization and specificity for a variety of TROP2 expressing solid tumors and secondarily, through a wt FC receptor mediating innate immune effector functions toward the cancer cells. Upon antibody mediated internalization, BL-M02D1 is trafficked to cancer cell lysosomes and liberates its therapeutic payload that induces genotoxic stress activating pathways leading to cancer cell death.

BL-M02D1 is currently being evaluated as a single agent in clinical trials enrolling patients with a variety of TROP2+ solid tumor types.